BMY Latest Press Releases

-- September 18, 2026 --

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 Business Wire 6:59 AM

-- September 17, 2026 --

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years Business Wire 6:59 AM

-- September 16, 2026 --

Bristol Myers Squibb Announces Dividend Business Wire 6:59 AM

-- September 10, 2026 --

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market Globe Newswire 8:30 AM

-- September 8, 2026 --

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... Business Wire 6:59 AM

-- August 29, 2026 --

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 Business Wire 11:00 AM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

-- August 13, 2026 --

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS , in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Business Wire 5:12 PM

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PRNewswire 8:00 AM

-- August 10, 2026 --

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas Business Wire 9:01 AM

-- July 30, 2026 --

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 Business Wire 6:59 AM

-- July 20, 2026 --

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA Business Wire 6:59 AM

-- July 13, 2026 --

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma Business Wire 6:59 AM

-- June 24, 2026 --

The Quest to Repair What Multiple Sclerosis Takes Away Globe Newswire 8:30 AM

-- June 18, 2026 --

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 Business Wire 6:59 AM

-- June 17, 2026 --

Bristol Myers Squibb Announces Dividend Business Wire 4:16 PM

-- June 8, 2026 --

Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Business Wire 6:59 AM

-- June 3, 2026 --

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer Business Wire 8:00 AM

-- June 2, 2026 --

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma Business Wire 8:00 AM

-- June 1, 2026 --

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Business Wire 6:59 AM

Bristol Myers Squibb Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Business Wire 6:55 AM

-- May 30, 2026 --

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial Globe Newswire 2:15 PM

-- May 29, 2026 --

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma Business Wire 8:00 AM

-- May 27, 2026 --

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 6:59 AM

-- May 21, 2026 --

Bristol Myers Squibb to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Business Wire 5:01 PM

-- May 20, 2026 --

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations Business Wire 6:59 AM

-- May 14, 2026 --

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience Business Wire 8:30 AM

-- May 12, 2026 --

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees Globe Newswire 4:01 PM

-- May 8, 2026 --

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Business Wire 6:59 AM

-- May 6, 2026 --

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026 Business Wire 6:59 AM

-- May 4, 2026 --

Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026 Business Wire 6:59 AM

-- April 30, 2026 --

Bristol Myers Squibb Reports First Quarter Financial Results for 2026 Business Wire 6:59 AM

-- April 24, 2026 --

Bristol Myers Squibb and Pfizer to Make Eliquis (apixaban) Available via Mark Cuban Cost Plus Drug Company Business Wire 6:59 AM

-- April 23, 2026 --

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PRNewswire 8:00 AM

-- April 21, 2026 --

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion Business Wire 7:00 AM